Zacks Research Has Negative Outlook for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research decreased their Q1 2025 earnings estimates for Corcept Therapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.17 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.63 EPS and Q1 2026 earnings at $0.45 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million.

Several other research firms have also recently weighed in on CORT. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler raised their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $115.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, February 27th. Finally, Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $59.47 on Monday. The business’s 50 day moving average is $61.66 and its 200-day moving average is $54.13. The firm has a market cap of $6.27 billion, a P/E ratio of 47.20 and a beta of 0.61. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $75.00. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Corcept Therapeutics

A number of large investors have recently modified their holdings of CORT. Norges Bank acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth $42,055,000. Jacobs Levy Equity Management Inc. raised its stake in Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after acquiring an additional 352,947 shares in the last quarter. Braun Stacey Associates Inc. acquired a new position in Corcept Therapeutics during the fourth quarter worth about $14,935,000. FMR LLC lifted its holdings in shares of Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after acquiring an additional 269,074 shares during the last quarter. Finally, Synergy Asset Management LLC boosted its stake in shares of Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after purchasing an additional 262,503 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling

In other news, CEO Joseph K. Belanoff sold 2,924 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $60.91, for a total transaction of $178,100.84. Following the completion of the sale, the chief executive officer now owns 3,019,411 shares of the company’s stock, valued at approximately $183,912,324.01. This represents a 0.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now directly owns 85,318 shares in the company, valued at $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,627 shares of company stock worth $2,557,674. Company insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.